CSL reports US$2.6B full year loss
- CSL posted a US$2.6 billion net loss for the 12 months ended June 30 after taking one-off restructuring costs and impairments.
- The company maintained its final dividend at US$1.62 per share while operating cash flow held at US$3.5 billion.
- Executives plan to spend US$1.5 billion expanding US plasma manufacturing to return the business to sustainable growth.
CSL (ASX:CSL) reported a US$2.6 billion net loss after tax for FY26 as one-off restructuring costs and impairments offset underlying earnings.
The statutory loss compares with underlying net profit after tax of US$3.1 billion, which fell 2% from the prior period. Cashflow from operations was US$3.5 billion.
“Plasma market fundamentals and demand remain robust, and momentum is building behind our newer therapies, such as ANDEMBRY and HEMGENIX,” said CSL Interim CEO and Managing Director Gordon Naylor.
One-off pre-tax restructuring costs totalled $799 million, though the 12-month transformation programme delivered $176 million in cost savings.
The company recognised pre-tax impairments of $5.5 billion in the second half of FY26, resulting in total pre-tax impairments of $7.1 billion in FY26.
Following the announcement, the CSL share price was unchanged at $134.60.
In FY27 CSL expects revenue to be in line with the prior year and underlying NPAT growth of approximately 5%.
Management streamlined operations by integrating commercial affairs across the Behring and Vifor units to eliminate duplication.
